Under the terms of the agreement, Nxera will be responsible for the supply of drug product and Holling will be responsible for regulatory, commercial and distribution activities and will hold all ...

The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia Pharmaceuticals ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront. The drug in question is cenerimod, a S1P1 receptor modulator currently ...

THE first phase of the new data centre campus, jointly developed by Telekom Malaysia Bhd (TM) and Singapore’s Nxera, is expected to be completed in 2026 to add to the high-quality digital ...

Nxera Pharma, with major operations in Cambridge and Tokyo, has negotiated a lucrative deal in the autoimmune diseases space in Asia-Pacific. It has entered an assignment agreement with Viatris Inc, a ...

Singapore’s Infocomm Media Development Authority ... security and resilience in the industry.” Bill Chang, CEO of Nxera, Singtel’s datacentre arm, welcomed the new guidelines, adding ...

The transaction included an option for Nxera Pharma - upon payment of separate option fees ... New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam. Idorsia Ltd is reaching ...